Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Trial looks at telmisartan in treating non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

3 Mar 2009

Liver tumors associated with metabolic syndrome differ from other tumors

Liver cancer in patients whose only risk factor is metabolic syndrome has distinct forms and structures compared to other liver tumors.

25 Feb 2009

Targeting the protein AEG1 impairs human liver cancer growth in mice

Hepatocellular carcinoma (HCC) is a highly aggressive form of liver cancer and one of the 5 most common cancers worldwide.

17 Feb 2009

Radioimmunotherapy shows promise for HIV infection and viral cancers

Scientists at Albert Einstein College of Medicine of Yeshiva University have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that selectively target and destroy microbial and HIV-infected cells.

16 Feb 2009

Capn4 protein predicts liver cancer recurrence and after transplantation

A new study suggests that Capn4, a protein involved in cell migration, is associated with liver cancer recurrence and metastasis after liver transplantation.

3 Feb 2009

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer.

21 Jan 2009

Bariatric surgery may resolve liver disease

Obesity is a growing epidemic in the U.S. with a significant increase in prevalence from 15 percent to 32.9 percent from 1980 to 2004. Nonalcoholic fatty liver disease (NAFLD) is an emerging problem related to the obesity epidemic, becoming one of the most common causes of liver disease in the nation.

1 Dec 2008

Protherics announces start of Prolarix phase 2 study in liver cancer

Protherics PLC today announced the initiation of a phase 2a proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treaent of primary liver cancer (hepatocellular carcinoma or "HCC"). This follows promising data from a phase 1 study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 June 2008.

27 Aug 2008

Hunt for baby denied HBV shot

Authorities in New South Wales, Australia, continue to search for a couple who have refused to have their newborn baby immunised against hepatitis B.

25 Aug 2008

Radioimmunotherapy targeting viral antigens shows potential to treat or prevent viral cancers

A new study, presented at the Society of Nuclear Medicine's 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.

16 Jun 2008

Hepatitis C therapy peginterferon alfa-2b shows promise

The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

24 Apr 2008

Treatment with sunitinib slows tumor growth and spread of liver cancer

Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver, researchers report.

15 Apr 2008

Targeted therapy combo overcomes treatment resistance in liver cancer

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

13 Apr 2008

Combination therapy improves survival time for patients with more advanced liver cancer

Combining a type of chemotherapy with radiothermal therapy resulted in longer survival time for patients with advanced liver cancer, compared to receiving the therapies alone, according to a study in the April 9 issue of JAMA, the Journal of the American Medical Association.

9 Apr 2008